Model diagram of strategies for <i>P</i>. <i>vivax</i> treatment in females.

<p>Model diagram of strategies for <i>P</i>. <i>vivax</i> treatment in females.</p

One-way sensitivity analysis results on costs and disability-adjusted life-years (DALYs) for the comparison of the screening strategy with the chloroquine strategy in males.

<p>The ranges used are specified in <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005602#pntd.0005602.t002" target="_blank">Table 2</a>. See <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005602#pntd.0005602.s003" target="_blank">S3 Appendix</a> for all one-way sensitivity analysis results.</p

Costs and disability adjusted life year (DALY) results over one year per primary episode treated in the base case analysis and probabilistic sensitivity analysis (PSA).

<p>All costs are in 2014 United States Dollars.</p

Model diagram of strategies for <i>P</i>. <i>vivax</i> treatment in males.

<p>Model diagram of strategies for <i>P</i>. <i>vivax</i> treatment in males.</p

The table shows simulated outcomes for 1000 <i>P</i>. <i>vivax</i> malaria patients of undetermined G6PD status at attendance, if they were managed according to each of three strategies (chloroquine, primaquine and screening) according to G6PD status, treatment given and the test result if screened.

<p>The table shows simulated outcomes for 1000 <i>P</i>. <i>vivax</i> malaria patients of undetermined G6PD status at attendance, if they were managed according to each of three strategies (chloroquine, primaquine and screening) according to G6PD status, treatment given and the test result if screened.</p

Two-way sensitivity analysis results showing the impact of changes in the level of adherence to primaquine regimens.

<p>Green represents disability-adjusted life-years (DALYs) averted by the screening strategy for a cohort of 1000 individuals. For costs, yellow indicates increased costs and blue indicates cost savings for the screening strategy for one individual. For net monetary benefit (<i>NMB</i>), purple indicates scenarios where the screening strategy would be cost-effective at a threshold of US$500 (<i>T</i>) where <i>NMB = T × ΔDALYs– ΔCosts</i>.</p

Model parameters and sources.

<p>All costs are listed in 2014 United States Dollars.</p

Summary of key components of each strategy.

<p>Summary of key components of each strategy.</p